Therefore, GPRC5D protein, similar to BCMA, represents an attractive target for monoclonal antibody-based (e.g., bispecific T-cell-engaging antibodies or antibody–drug conjugates) or cell-based (e.g., CAR-T or CAR-NK) immunotherapy in MM. Here, TNFRSF17 is linked to Miyoshi myopathy.